胆管癌患者p53血清学和免疫组化联合检测的临床意义  

Clinical signifcance of p53 by serological and immunohistochemical detection in patients with cholangiocarcinoma

作　　者：丁谷华[1] 孔雷[1] 奉典旭[1] 王宝华[2] 蔡瑞霞[2] 沈江帆[3] 韩峰[1] 

机构地区：[1]上海中医药大学附属普陀医院普外科,上海200062 [2]上海中医药大学附属普陀医院病理科,上海200062 [3]上海中医药大学附属普陀医院核医学科,上海200062

出　　处：《肝胆胰外科杂志》2007年第3期171-173,共3页Journal of Hepatopancreatobiliary Surgery

摘　　要：目的探讨胆管癌患者p53血清学和免疫组化联合检测的临床意义。方法本组包括42例手术治疗的胆管癌患者。ELISA法测定患者外周血和门静脉血p53抗体;免疫组化法检测胆管癌组织中突变p53蛋白。结果外周静脉血途径检测p53抗体阳性3例(占7.1%,3/42),阳性率显著低于门静脉血途径阳性率(占52.4%,22/42)和肿瘤组织p53蛋白阳性率(占71.4%,30/42)。胆管癌术后早期复发者门静脉血p53抗体阳性、胆管癌组织p53蛋白表达均显著高于未复发者。结论联合门静脉血和癌组织p53突变检测可能有助于判断胆管癌患者的预后。Objective To investigate the clinical signifcance of p53 by serological and immunohistochemical detection in patients with cholangiocarcinoma. Methods The clinical data of 42 patients with cholangiocarcinoma who underwent surgical treatment from February 2001 to February 2005 were analyzed retrospectively, p53 antibody in perpheral and blood in the portal vein were determined with ELISA and mutated p53 protein in cholangiocarcinoma was detected with immunohistochemical method. Results The positive rate of p53 antibody in perpheral venous blood was 7,1% （3/42）, which was remarkably lower than that in portal venous blood （52,4%,22/42） or cholangiocarcinoma （71,4%,30/42）, respsectively. The positive rate of p53 antibody in portal venous blood or cholangiocarcinoma of early recurrent operated patients was markedly higher compared with that in cases who did not recur. Conclusion Combined detection of mutated p53 protein in portal venous blood or cholangiocarcinoma will be valuable in prognostic evaluation of patients with cholangiocarcinoma.

关 键 词：胆管肿瘤 基因 p53 联合检测 血清学 免疫组织化学 

分 类 号：R735.8[医药卫生—肿瘤]